95.149.161.164: /* Management */

2023-06-03T14:01:37Z

Management

95.149.161.164 at 14:00, 3 June 2023

2023-06-03T14:00:31Z

Show changes

>Paris: Created page with "== SummarySource: Yahoo Finance. == Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SAR..."

2022-08-15T07:55:34Z

Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SAR..."

New page

== Summary<ref>Source: Yahoo Finance.</ref> ==

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

== References and notes ==
[[Category:Thesis]]
__INDEX__

← Older revision		Revision as of 15:01, 3 June 2023
Line 7:		Line 7:
	The Avacta Group Board of Directors provide experienced strategic and practical guidance to the Company to help ensure that the interests of all shareholders are met and that corporate good practice is followed.		The Avacta Group Board of Directors provide experienced strategic and practical guidance to the Company to help ensure that the interests of all shareholders are met and that corporate good practice is followed.

	Dr Eliot Forster Non-executive Chairman		==== Dr Eliot Forster Non-executive Chairman ====

	Eliot was appointed as Chairman to the Board in June 2018, bringing with him three decades of experience in the pharmaceutical and biotechnology industry. He is currently the Chief Executive Officer of F-star and also Non-executive Director of Immatics NV, a clinical stage biopharmaceutical company developing TCR-based therapeutics for the treatment of cancer (NASDAQ IMTX). Prior to joining F-star, Eliot was Chief Executive Officer at Immunocore, Creabilis Therapeutics and Solace Pharmaceuticals Inc. The early part of Eliot’s career was at GSK and Pfizer.		Eliot was appointed as Chairman to the Board in June 2018, bringing with him three decades of experience in the pharmaceutical and biotechnology industry. He is currently the Chief Executive Officer of F-star and also Non-executive Director of Immatics NV, a clinical stage biopharmaceutical company developing TCR-based therapeutics for the treatment of cancer (NASDAQ IMTX). Prior to joining F-star, Eliot was Chief Executive Officer at Immunocore, Creabilis Therapeutics and Solace Pharmaceuticals Inc. The early part of Eliot’s career was at GSK and Pfizer.

Line 15:		Line 14:
	Eliot is a member of the Remuneration Committee and the Audit Committee.		Eliot is a member of the Remuneration Committee and the Audit Committee.

	Dr Alastair Smith Chief Executive Officer		==== Dr Alastair Smith Chief Executive Officer ====

	Alastair was the Founder of Avacta and has been Chief Executive Officer since its inception in 2005. Alastair has extensive management, strategic planning and transactional experience, having led the public and private M&A activities of the Group including the IPO of the Group in 2006 via a reverse merger. He is well known in the UK public markets; a respected and trusted executive with many years’ experience of investor relations in the UK, Europe and the US. He has successfully delivered multiple follow-on fundraisings for the Group.		Alastair was the Founder of Avacta and has been Chief Executive Officer since its inception in 2005. Alastair has extensive management, strategic planning and transactional experience, having led the public and private M&A activities of the Group including the IPO of the Group in 2006 via a reverse merger. He is well known in the UK public markets; a respected and trusted executive with many years’ experience of investor relations in the UK, Europe and the US. He has successfully delivered multiple follow-on fundraisings for the Group.

Line 23:		Line 21:
	Alastair is a scientist by training with a degree and PhD in Physics from Manchester University. Following a period of working in the US, he returned in 1995 to take up an academic position at Leeds University, becoming Professor of Molecular Biophysics at the age of 38. Over a ten-year period, through close collaboration with life scientists, he built one of the leading biophysics research groups in Europe before leaving his academic career in 2007 to focus full time on delivering value to Avacta shareholders.		Alastair is a scientist by training with a degree and PhD in Physics from Manchester University. Following a period of working in the US, he returned in 1995 to take up an academic position at Leeds University, becoming Professor of Molecular Biophysics at the age of 38. Over a ten-year period, through close collaboration with life scientists, he built one of the leading biophysics research groups in Europe before leaving his academic career in 2007 to focus full time on delivering value to Avacta shareholders.

	Tony Gardiner Chief Financial Officer		==== Tony Gardiner Chief Financial Officer ====

	Tony joined Avacta in 2016 as Chief Financial Officer and is a member of the Institute of Chartered Accountants of England and Wales. He has over 25 years’ experience of senior financial and operational management roles across several different sectors including extensive M&A transactional and fundraising experience. Between 2007 and 2011, Tony was the Chief Financial Officer of AIM-listed Fusion IP plc, an IP commercialisation company, which was subsequently acquired by IP Group plc in 2014. He played a key role in supporting the growth of the business and oversaw all finance activities as well as directly supporting life sciences and health technology companies in Fusion’s portfolio.		Tony joined Avacta in 2016 as Chief Financial Officer and is a member of the Institute of Chartered Accountants of England and Wales. He has over 25 years’ experience of senior financial and operational management roles across several different sectors including extensive M&A transactional and fundraising experience. Between 2007 and 2011, Tony was the Chief Financial Officer of AIM-listed Fusion IP plc, an IP commercialisation company, which was subsequently acquired by IP Group plc in 2014. He played a key role in supporting the growth of the business and oversaw all finance activities as well as directly supporting life sciences and health technology companies in Fusion’s portfolio.

	Prior to joining Avacta, Tony worked for AHR (formerly Aedas), an international architecture and building consultancy practice, where he had been Finance Director since 2011. Tony has also held senior finance roles within Eversheds LLP, KCOM Group plc and Hickson International.		Prior to joining Avacta, Tony worked for AHR (formerly Aedas), an international architecture and building consultancy practice, where he had been Finance Director since 2011. Tony has also held senior finance roles within Eversheds LLP, KCOM Group plc and Hickson International.

	Dr Trevor Nicholls Non-executive Director		==== Dr Trevor Nicholls Non-executive Director ====

	Trevor brings considerable experience in the commercialisation of innovative life science technologies from his previous roles as Non-executive Chairman of Oxford Nanopores Technologies, Chief Commercial Officer at Affymetrix, founder and Chief Executive Officer of UK biotech company Oxagen Ltd and Commercial Director of the Life Sciences business at Amersham International (now part of Danaher Corporation).		Trevor brings considerable experience in the commercialisation of innovative life science technologies from his previous roles as Non-executive Chairman of Oxford Nanopores Technologies, Chief Commercial Officer at Affymetrix, founder and Chief Executive Officer of UK biotech company Oxagen Ltd and Commercial Director of the Life Sciences business at Amersham International (now part of Danaher Corporation).

Line 37:		Line 33:
	Trevor is also Non-executive Chairman of Fargro Limited a provider of products and services for Horticulture, Nonexecutive Chairman of Iota Sciences Limited, a spin-out company from the University of Oxford which is commercialising innovative microfluidic technology for the life sciences sector, a Non-executive Director of Conidia Bioscience Limited, which develops and sells patented lateral flow tests for the detection of microbial contamination of aviation and diesel fuels, and a Nonexecutive Director of Wobble Genomics Ltd, a spin-out of the Roslin Institute, specialising in DNA analytics and diagnostics. Previously Trevor has been Non-executive Chairman of Activiomics Limited, a biomarker discovery specialist, as well as a Non-executive Director of hVivo plc, a clinical research organisation. Trevor is Chair of the Remuneration Committee and a member of the Audit Committee.		Trevor is also Non-executive Chairman of Fargro Limited a provider of products and services for Horticulture, Nonexecutive Chairman of Iota Sciences Limited, a spin-out company from the University of Oxford which is commercialising innovative microfluidic technology for the life sciences sector, a Non-executive Director of Conidia Bioscience Limited, which develops and sells patented lateral flow tests for the detection of microbial contamination of aviation and diesel fuels, and a Nonexecutive Director of Wobble Genomics Ltd, a spin-out of the Roslin Institute, specialising in DNA analytics and diagnostics. Previously Trevor has been Non-executive Chairman of Activiomics Limited, a biomarker discovery specialist, as well as a Non-executive Director of hVivo plc, a clinical research organisation. Trevor is Chair of the Remuneration Committee and a member of the Audit Committee.

	Paul Fry Non-executive Director		==== Paul Fry Non-executive Director ====

	Paul was appointed as a Nonexecutive Director in February 2020. Paul has extensive financial experience across several industries including biotech, pharmaceutical and telecommunications. Paul is currently Chief Financial Officer of Argenta, a global CRO and CDMO specialising in animal health. Prior to this he was Chief Financial Officer of Vectura Group Ltd, an industry-leading inhaled drug delivery specialist which up until 2021 was listed on the FTSE Main Market.		Paul was appointed as a Nonexecutive Director in February 2020. Paul has extensive financial experience across several industries including biotech, pharmaceutical and telecommunications. Paul is currently Chief Financial Officer of Argenta, a global CRO and CDMO specialising in animal health. Prior to this he was Chief Financial Officer of Vectura Group Ltd, an industry-leading inhaled drug delivery specialist which up until 2021 was listed on the FTSE Main Market.

Line 47:		Line 42:
	Paul is Chair of the Audit Committee and a member of the Remuneration Committee.		Paul is Chair of the Audit Committee and a member of the Remuneration Committee.

	Dr Mark Goldberg		==== Dr Mark Goldberg Non-executive Director ====

	Non-executive Director

	Mark was appointed as a Non-executive Director in August 2021 and is a medical oncologist, haematologist and a biotechnology executive. Mark currently serves on the boards of ImmunoGen, GlycoMimetics, Blueprint Medicines, and Walden Biosciences.		Mark was appointed as a Non-executive Director in August 2021 and is a medical oncologist, haematologist and a biotechnology executive. Mark currently serves on the boards of ImmunoGen, GlycoMimetics, Blueprint Medicines, and Walden Biosciences.

Line 59:		Line 51:
	Mark received his AB from Harvard College (magna cum laude) and his MD (cum laude) from Harvard Medical School (Harvard MIT Program in Health Sciences and Technology).		Mark received his AB from Harvard College (magna cum laude) and his MD (cum laude) from Harvard Medical School (Harvard MIT Program in Health Sciences and Technology).

	Dr Christina Coughlin Non-executive Director		==== Dr Christina Coughlin Non-executive Director ====

	Christina was appointed as a Nonexecutive Director in March 2022. Christina is the Chief Executive Officer of Cytolmmune Therapeutics LLC, which is a clinical stage biotechnology company focused on development and commercialisation of novel cancer immunotherapy products designed to use the patient’s own immune system to eliminate cancer cells. Christina has a broad background in biotechnology and global pharmaceuticals, with a comprehensive drug development background from pre-IND to filing experience and has a track record of building drug development teams in global companies.		Christina was appointed as a Nonexecutive Director in March 2022. Christina is the Chief Executive Officer of Cytolmmune Therapeutics LLC, which is a clinical stage biotechnology company focused on development and commercialisation of novel cancer immunotherapy products designed to use the patient’s own immune system to eliminate cancer cells. Christina has a broad background in biotechnology and global pharmaceuticals, with a comprehensive drug development background from pre-IND to filing experience and has a track record of building drug development teams in global companies.

Avacta Group Plc - Revision history

95.149.161.164: /* Management */

95.149.161.164 at 14:00, 3 June 2023